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Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. Conventional cytotoxic chemotherapy has failed to
show a substantial benefit for patients with HCC. Recently, a number of new drugs targeting molecular mechanisms involved in liver
cell transformation have entered into clinical trials and led to encouraging results. In this review we summarise this data and point to a
number of new compounds, which are currently being tested and can potentially broaden our therapeutic arsenal even further.
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Hepatocellular carcinoma is the third most common cause of
cancer-related death worldwide with 600000 patients dying of this
disease every year (Parkin et al, 2005). Although patients with
early-stage disease have an excellent prognosis with a 5-year
survival of more than 75–80%, there has been no effective therapy
available for those with advanced disease, who are not eligible for
transarterial chemoembolisation. We have reported earlier that
50% of HCC patients are diagnosed at an advanced stage (Greten
et al, 2005). Recent advances in the development of targeted
therapies have now also shown promising results. Here, we will
discuss the results obtained using different molecular targeting
agents and suggest new pathways for development of therapeutic
options for HCC.
MOLECULAR CARCINOGENESIS
More than 80% of all HCC occur in patients with liver cirrhosis.
Chronic viral infections as well as alcoholic liver disease are the
most common etiologies of liver cirrhosis and also represent the
initiation point of hepatocarcinogenesis (El-Serag and Rudolph,
2007). Continuous cell death, which induces the release of different
cytokines, as well as fibrogenesis and development of liver
cirrhosis have been identified as early factors responsible for
carcinogenesis. Integration of hepatitis B virus (HBV) DNA into
the host genome not only induces chromosomal instability, but
depending on the site of DNA integration may also activate
oncogenes or inactivate tumour-suppressor genes. Moreover, viral
proteins (HBx and preS) have oncogenic properties. HBx activates
different promoter elements and triggers activation of transcrip-
tion factors such as AP-1 and NF-kB. Through this activity, genes,
which are involved in cell cycle control, as well as apoptosis, are
affected. A different molecular pathway has been suggested for
hepatitis C virus (HCV)-induced hepatocarcinogenesis. In this
case, HCV core protein affects cellular proliferation and apoptosis.
In addition, chronic HCV infection can cause major immune
responses, which might ultimately support hepatocarcinogenesis.
TUMOUR ANGIOGENESIS
Hepatocellular carcinoma is a highly vascularised tumour, which
makes vascular targeting approaches appealing for the treatment
of HCC. Two studies using the endothelial marker CD34 to identify
neovascularisation have reported that high microvessel density
was a significant predictor to poor disease-free survival after
resection (Ho et al, 2006; Wada et al, 2006; Poon et al, 2007). The
mechanisms responsible for angiogenesis in HCC are not
completely understood. However, one of the most important
stimuli for the formation of new tumour vessels is the interaction
of vascular endothelial growth factor (VEGF) with the VEGF
receptors 1 and 2. Vascular endothelial growth factor promotes the
growth, migration and morphogenesis of vascular endothelial cells
and increases vascular permeability. Although well-differentiated
HCC express higher levels of VEGF, it has also been shown that
circulating VEGF can be detected in patients with more
undifferentiated carcinomas (Torimura et al, 1998). Moreover, a
correlation between VEGF expression and survival has been
described (Poon et al, 2007). Other factors important for
neoangiogenesis in HCC include fibroblast growth factor 2
(FGF2), angiogenin and angiopoietin.
GROWTH RECEPTORS
Tyrosine kinase receptors represent an attractive target for
molecular therapy of HCC. The Ras–MAP kinase (MAPK) signal
transduction pathway, as well as the phosphatidylinositol-3
(PI3K)–AKT kinase, are directly activated through the engage-
ment of different growth factor receptors. A number of growth
factor receptors are important in hepatocarcinogenesis such as the
epidermal growth factor receptor (EGFR), the fibroblast growth
factor receptor (FGFR), the hepatocyte growth factor receptor
(HGFR), the stem cell growth factor receptor (c-kit), the platelet
growth factor receptor (PDGFR) as well as the VEGF receptor.
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which initiates the activation of the Ras–Raf–ERK1/2 MAPK
signalling pathway and therefore ultimately leads to cell prolifera-
tion. A number of different small molecules, which are currently in
clinical use or under early clinical or preclinical evaluation, block
these pathways at different levels. There are a number of small
molecules targeting TK activity of EGFR that are being evaluated
for the treatment of HCC (Figure 1).
SORAFENIB FOR THE TREATMENT OF ADVANCED
HCC
The multi-tyrosine kinase inhibitor sorafenib is the first and so far
the only drug that has shown overall survival benefit in patients
with HCC in a multi-centre, double-blind, placebo-controlled
randomised phase III trial (SHARP trial). Median overall survival
increased from 7.9 months in the placebo group to 10.7 months in
the sorafenib group (hazard ratio in the sorafenib group, 0.69; 95%
confidence interval, 0.55–0.87; Po0.001) (Llovet et al, 2008b).
Sorafenib blocks the Ras–Raf kinase pathway in the tumour cell as
well as the VEGF and PDGF receptor on the endothelial cells
(Wilhelm et al, 2004). Although a number of studies suggest the
relevance of the Ras–Raf pathway in primary liver tumours,
surprisingly, only one study detected BRAF mutations in liver
tumours. However, these tumours were primary bile duct tumours
(Tannapfel et al, 2003) suggesting that a major mode of action in
the treatment of HCC is the potent antiangiogenic potential of
sorafenib. The most common grade 3 drug-related adverse events
observed in the SHARP study included diarrhoea and hand-foot
skin reaction, both of which occurred in 8% of all patients treated
with sorafenib. Recently, a survival benefit has also been shown for
Asian patients with advanced HCC treated with sorafenib. In this
study, the median overall survival increased from 4.1 months in
the placebo group to 6.2 months in the sorafenib group (hazard
ratio in the sorafenib group 0.67; 95% confidence interval, 0.49–
0.93; Po0.0155) (Cheng et al, 2008). Based on these two pivotal
studies sorafenib has become the new standard of care for patients
with advanced HCC. Future studies will define the role of sorafenib
also in the adjuvant setting or in combination with transarterial
chemoembolisation. Although until today no data is available on
the combination of sorafenib with other molecular targeting agents
for the treatment of HCC, one phase II study using the
combination of sorafenib and doxorubicin has been performed.
This study while showing good efficacy also revealed significant
doxorubicin-related toxicities (Abou-Alfa et al, 2008) (Table 1).
RESULTS FROM PHASE I AND II STUDIES TESTING
OTHER APPROVED TARGETING DRUGS
Sunitinib represents another small molecule that is currently being
evaluated in a phase III trial for the treatment of HCC. Sunitinib is
a multi-tyrosine kinase inhibitor that has already been approved
for the treatment of renal cell carcinoma as well as gastrointestinal
stroma tumours. It targets receptor tyrosine kinases of the split-
kinase domain family such as VEGFR-1 and -2, PDGFR-a and
PDGFR-b, c-kit and FLT3 and the RET kinase (O’Farrell et al,
2003). A number of different preclinical models have shown an
enhanced efficacy of tyrosine kinase inhibitors if the VEGF
receptors on surrounding endothelial cells as well as the PDGF
receptors on pericytes are blocked simultaneously. Results from
different phase II studies in which patients with unresectable and
metastasised HCC were treated with 37.5mg sunitinib daily are
shown in Table 1. This treatment was reasonably well tolerated and
9 out of 19 patients showed stable disease 12 weeks after initiation
of treatment. A partial response was observed in one patient and a
decrease in tumour permeability in a number of patients (Zhu
et al, 2007a). In a second study in patients with unresectable HCC,
patients were treated with 50mg sunitinib daily. Although one
patient showed a partial response in this study, the sunitinib
dosage had to be reduced in 27% of the patients due to adverse
effects. In five cases an acute decompensation of the liver cirrhosis
was observed (Faivre et al, 2007).
Erlotinib at a dosage of 150mg daily has been evaluated in two
independent phase II trials in patients with advanced HCC.
Although the objective tumour response rates observed were only
minor (6% in one trial and no responses in the other trial), stable
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Figure 1 Schematic overview of key pathways in carcinogenesis and molecularly targeted therapy in hepatocellular carcinoma.
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(Philip et al, 2005; Thomas et al, 2007a), with a PFS rate of 32 and
28% after 6 months and 24 weeks. Lapatinib, a different EGFR
tyrosine kinase inhibitor, has shown promising results in a phase
II trial with 2 out of 17 partial responses and a modest PFS of 2.3
months (Ramanathan et al, 2006) (Table 1). Moreover, gefitinib, an
oral EGFR tyrosine kinase inhibitor has been tested in
patients with advanced HCC as a single agent. However, the
authors have concluded that gefitinib was not effective in patients
with advanced HCC (O’Dwyer et al, 2006) (Table 1). Cetuximab, an
EGFR blocking antibody, has been tested in multiple phase II
trials. Zhu and colleagues reported a PFS of 1.4 months (Zhu et al,
2007b) and no objective responses. In our study we observed
similar results with a TTP of 2 months (Grunwald et al, 2007)
(Table 1).
Bevacizumab is a recombinant humanised antibody directed
against VEGF. It has been approved in the United States by the
FDA for the treatment of a number of different tumours including
colorectal cancer, non-small-cell lung cancer and breast carcino-
ma. Partial responses have been observed in patients after
bevacizumab monotherapy and disease stabilisation in 30% of
treated patients has been documented (Siegel et al, 2008).
Combination treatment of bevacizumab with EGFR targeting
agents was shown to be safe and revealed promising initial results
with a median time to progression of 9 months (Thomas et al,
2007b) (see Table 1). Overall, bevacizumab has shown promising
results as a single agent as well as in combination with other
targeted therapies and cytotoxic therapy (Zhu et al, 2006)
supporting the idea of a vascular targeting therapy for the
treatment of HCC.
REPORTS FROM CLINICAL TRIALS TESTING NEW
MOLECULAR TARGETING DRUGS FOR THE
TREATMENT OF HCC
AZD2171 is another small molecule, which by blocking the
tyrosine kinase activity of VEGFR, PDGFR and c-kit, has shown
remarkable effects in the treatment of glioblastoma. It has also
been tested in a phase II trial in patients with non-resectable HCC.
However, 84% of the patients experienced grade 3 toxicities at a
dosage of 45mg (Alberts et al, 2007). It remains an open question
why AZD2171 was so poorly tolerated in patients with HCC. One
possible explanation could be the underlying liver cirrhosis, which
can impair drug metabolism significantly.
PTK787 is a compound that inhibits VEGFR1, VEGFR2,
VEGFR3, PDGFR-b, Flt-3 and kit. It was tested in a phase III
trial in patients with advanced colorectal cancer. However, the
results from that trial were negative. In a murine HCC model oral
administration of PTK787 induced tumour cell apoptosis and
reduced vessel formation (Liu et al, 2005). Induction of hypoxia
through ligation of the hepatic artery enhanced this effect (Yang
et al, 2006). PTK787 might therefore represent an interesting
combination treatment with transarterial chemoembolisation. The
maximal tolerated dose was determined to be 750mg daily in a
phase I study of 18 patients with HCC and disease stabilisation was
observed in 9 patients (Koch et al, 2005).
ZD6474 is a new oral inhibitor of VEGF receptors that
additionally targets the EGFR/HER1 receptor. This drug has
shown significant antitumour activity in preclinical tumour
models and experimental data also suggests that it might inhibit
metastasis formation. It is currently being tested in a phase II trial
in patients with HCC. A phase I/II study of TSU-68, an oral
angiogenesis inhibitor, which targets VEGF, b-FGF and PDGF, has
shown good tolerability of this drug and preliminary data suggest
its antitumour activity in patients with HCC. Brivanib, an oral
VEGFR and FGFR tyrosine kinase inhibitor, is currently being
tested in a phase I and II study in HCC patients and a phase III
trial is being planned.
COMPOUNDS IN EARLY DEVELOPMENT FOR THE
TREATMENT OF HCC
AZD6244 is a new MEK inhibitor, which is being evaluated for the
treatment of HCC in preclinical models. The MEK inhibitor,
PD0325901, which can be administered orally, has been evaluated
in TGF-a transgenic mice in which liver cancers were induced by
diethylnitrosamine treatment. PD0325901 led to a significantly
smaller number of premalignant tumour cells in the treatment
group. So far there is no data available on the effect of MEK
inhibitors in patients with HCC.
The PI3K pathway is activated by a number of different growth
factors and cytokines. PI3K activation leads to the expression of
Table 1 Summary of efficacy results obtained in recent phase II clinical trials using molecular therapies for the treatment of HCC in comparison to the
results obtained with sorafenib in the SHARP phase III trial
Regimen
No. of
patients RR %
Median PFS (P)/
TTP (T), months
PFS at
6 months, %
Median survival,
months Reference
Erlotinib 38 9 3.2 (P) 32 13 Philip et al (2005)
Erlotinib 40 0 3.1 (P) 28 6.3 Thomas et al (2007a)
Gefitinib 31 3 2.8 (P) NR 6.5 O’Dwyer et al (2006)
Lapatinib 30 5 2.3 (P) NR 6.2 Ramanathan et al (2006)
Cetuximab 30 0 1.36 (P) 3 9.6 Zhu et al (2007b)
Cetuximab 32 0 1.87 (T) NR NR Grunwald et al (2007)
Cetuximab-GemOx 43 23 4.5 (P) NR 9.2 Louafi et al (2007))
CapeOx+Cetux 25 33 4.3 (T) NR NR O’Neil et al (2008)
Bevacizumab 46 13 6.9 (P) 65 12,4 Siegel et al (2008)
Bevacizumab 24 12.5 NR NR NR Malka et al (2007)
GemOx+Beva 33 20 5.3 (P) 48 9.6 Zhu et al (2006)
CapeOx+Beva 30 10 5.4 (P) 40 NR Sun et al (2007)
Cape+Beva 25 16 4.1 (P) 34 10.7 Hsu et al, (2007)
Beva+Erlotinib 34 21 9 (P) 75 (at 4 months) 19 Thomas et al (2007b)
Sunitinib 26 3.8 4.1 (P) 35 11.6 Zhu et al (2007a)
Sunitinib 37 2.7 5.2 (P) 35 11.2 Faivre et al (2007)
Sunitinib 23 6 NR NR NR Hoda et al (2008)
Sorafenib+Doxo 47 4 8.6 (T) NR 13.7 (6.5 for placebo) Abou-Alfa et al (2008)
Sorafenib 300 2.3 5.5 (T) 62 (at 4 months) 10.7 (7.9 for placebo) Llovet et al (2008b)
NR¼not reported; PFS¼progression free survival; RR¼response rate; TTP¼time to progression.
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kinase. AKT has multiple cellular targets, which suppress
induction of apoptosis in the cell. One important substrate of the
AKT kinase is the ‘mammalian target of rapamycin’ protein family
(mTOR). The mTOR regulates the activation of p70 S6 kinase and
the translational repressor proteins PHAS-1/4E-BP. These proteins
control the cell cycle and have therefore an impact on cell
proliferation. AKT activation is antagonised by the expression of
the lipid phosphatase PTEN. In recent years, different molecules
have been developed which target this pathway at various steps.
The sphingosine receptor inhibitor FTY720 controls PI3K activity
by inhibition of rac proteins. Treatment of HCC cells with FTY720
results in reduced cell motility, which might affect metastasis
formation (Lee et al, 2005). The macrolid antibiotic rapamycin
binds cytoplasmic FK506 binding protein (FKBP12) thereby
inhibiting mTOR activity. This might be one reason why, sirolimus
as well as its derivates block growth of tumours with an activated
PI3K–AKT signal transduction cascade. The activity of PTEN is
reduced in more than 50% of all HCC. In addition, hepatocyte
specific knockout of PTEN promotes hepatocarcinogenesis in
mice. Mammalian target of rapamycin inhibitors such as sirolimus
suppress the proliferation of hepatoma cells in vitro as well as in
vivo in a xenotransplant model. Interestingly, the survival benefit
observed in mice correlated with a decreased vascularisation of
tumours in mice. Different mTOR inhibitors such as temsirolimus
and RAD001 are currently being evaluated in preclinical models of
HCC and first phase I/II trials have been initiated.
A different targeting pathway includes Wnt proteins that
function as ligands for the so-called Frizzled family of G-protein
coupled receptors. b-catenin is activated by the Wnt signal
transduction pathway and binds the transcription factor TCF
(T-cell factor) to initiate expression of a number of genes, which
are important for proliferation and cell survival including cyclin
D1, c-myc and others. Disturbing the Wnt signal transduction
cascade at different levels can cause a constitutive activation of this
pathway, which promotes hepatocarcinogenesis. Indeed, activating
mutations in the Wnt pathway have been observed in up to 40% of
all HCC. It should be noted at this point that Wnt pathway also
plays an important role in liver regeneration and proliferation of
stem cells opening the possibility to potentially inhibit the
proliferation of tumour stem cells. Although no molecules
targeting this pathway have made their way into clinical
evaluation, different drugs are currently in preclinical testing such
as PKF115-584 and CGP049090.
Epigenetic modifications of the genome (mainly hypermethyla-
tion of CpG island and histone deacetylation) accumulate during
hepatocarcinogenesis in chronically injured liver cells. It has been
shown that a large number of tumour-suppressor genes are
inactivated by epigenetic mechanisms in HCC. Success in
epigenetic therapy (such as 5-aza-2-deoxycytidine and SAHA)
has been achieved in both haematological malignancies and solid
tumours. In HCC cell lines, chemosensitivity can be potentiated by
epigenetic therapy. A multi-centre phase I/II trial on a novel
histone deacetylase inhibitor, PXD-101, is currently underway in
Hong Kong.
CONCLUSION
In contrast to haematological malignancies such as CML, no single
oncogenic event can be accused for the development of HCC.
Instead, a multitude of different signalling pathways are affected in
liver cancer cells making it difficult to focus molecular treatments.
The results of recent clinical trials and the advent of the first
systemic treatment for HCC point towards a multi-targeted
therapeutic approach to this disease. The demonstration of an
increase in overall survival of less than 3 months with the use of
sorafenib in patients with advanced HCC can only be the
beginning of a new era in the treatment of HCC. More drugs
potentially targeting alternative pathways need to be evaluated in
combination with sorafenib. In addition, more drugs targeting
similar molecules need to be evaluated compared with sorafenib as
recently suggested (Llovet et al, 2008a). However, understanding
the exact mechanisms involved in hepatocarcinogenesis remains
the fundamental condition for the development of new and more
potential drugs for the treatment of HCC.
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